**Highlights of This Issue 1839**

**THERAPEUTIC DISCOVERY**

1841  
First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer  
Leyre Brizuela, Isabelle Ader, Catherine Mazeronnes, Magalie Bocquet, Bernard Malavaud, and Olivier Cuvillier

1852  
Induction of the Transcriptional Repressor ZBTB4 in Prostate Cancer Cells by Drug-Induced Targeting of MicroRNA-17-92/106b-25 Clusters  
KyoungHyun Kim, Gayathri Chadalapaka, Satya S. Pathi, Un-Ho Jin, Ju-Seog Lee, Yun-Yong Park, Sung-Gook Cho, Sudhakar Chintharlapalli, and Stephen Safe

1863  
A Role for Homologous Recombination and Abnormal Cell-Cycle Progression in Radioresistance of Glioma-Initiating Cells  

1873  
Oxidative Stress Induced by Curcumin Promotes the Death of Cutaneous T-cell Lymphoma (HuT-78) by Disrupting the Function of Several Molecular Targets  
Mohammad Aslam Khan, Satindra Gahlot, and Sekhar Majumdar

1884  
Killing of Kras-Mutant Colon Cancer Cells via Rac-Independent Actin Remodeling by the βGBP Cytokine, a Physiological PI3K Inhibitor Therapeutically Effective In Vivo  
Livia Mallucci, Dong-yun Shi, Derek Davies, Peter Jordan, Alastair Nicol, Lavinia Lotti, Renato Mariani-Costantini, Fabio Verginelli, Valerie Wells, and Daniel Zicha

---

**PRECLINICAL DEVELOPMENT**

1894  
Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism  

1905  
Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways  
Xinqi Wu, Jingjing Li, Meijun Zhu, Jonathan A. Fletcher, and F. Stephen Hodi

1915  
Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models  
Xinhua Xie, Laisheng Li, Xiangsheng Xiao, Jiaoli Guo, Yanan Kong, Mingying Wu, Wanli Liu, Guoquan Gao, Jennifer L. Hsu, Weidong Wei, Mien-Chie Hung, and Xiaoming Xie

1925  
ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms  
Nousheen Zaidi, Ines Royaux, Johannes V. Swinnen, and Karine Smans

---

**Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts**  
Muralidharan Anbalagan, Alaa Ali, Ryan K. Jones, Carolyn G. Marsden, Mei Sheng, Latonya Carrier, Yahao Bu, David Hangauer, and Brian G. Rowan
<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1948</td>
<td>Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models</td>
<td>Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O’Connor</td>
</tr>
<tr>
<td>1959</td>
<td>TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells</td>
<td>Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, David J. Liewehr, Seth M. Steinberg, Sandra Silberman, Diane Palmieri, and Patricia S. Steeg</td>
</tr>
<tr>
<td>1968</td>
<td>Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target</td>
<td>Yongli Guo, Fadzai Chinyengetere, Andrey V. Dolinko, Alexandra Lopez-Aguirau, Yun Lu, Fabrizio Galimberti, Tian Ma, Qing Feng, David Sekula, Sarah J. Freeman, Angelina S. Andrew, Vincent Memoli, and Ethan Dmitrovsky</td>
</tr>
<tr>
<td>1988</td>
<td>YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels</td>
<td>Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicole Arradaza, Theodoros N. Teknos, and Pawan Kumar</td>
</tr>
<tr>
<td>2010</td>
<td>Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells</td>
<td>Yoko Matsuda, Masahito Hagiwara, Tomoko Seya, and Toshiyuki Ishiwata</td>
</tr>
</tbody>
</table>

**MOLECULAR MEDICINE IN PRACTICE**

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2006</td>
<td>MOLECULAR PROFILING OF PATIENTS WITH COLORECTAL CANCER AND MATCHED TARGETED THERAPY IN PHASE I CLINICAL TRIALS</td>
<td>Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, Cristina Saura, Teresa Macarulla, Elena Elz, Maria Alzina, Jaime Capdevila, Jose Perez-Garcia, Gessami Sanchez-Ollé, Claudia Aura, Ludmila Prudkin, Stefania Landolfi, Javier Hernandez-Losa, Ana Vivancos, and Josep Tabernero</td>
</tr>
</tbody>
</table>

**CORRECTION**

<table>
<thead>
<tr>
<th>Year</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>
ABOUT THE COVER

Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIc antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIc, which is a splicing isoform of FGFR2. FGFR2IIIc immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIc-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.
Molecular Cancer Therapeutics

11 (9)


Updated version  Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/9

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.